Replies to post #825072 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

Shouldn’t she be the 5th female phenom?

You already had another woman lined up as 4th female phenom from a few years ago. What’s going on with her? You seemed very excited about her couple of years ago and would post every day. LOL! ;)

[maverick_1]

Despite the legal uncertainties with any legal matter especially NWBO Spoofing Civil Suit at least it has gone down this pathway:

AND I have no legal background but my senses have never been wide of the mark of how this EPIC has evolved since 2014!

Re:
NorthWest Biotherapeutics Inc (NWBO)
Post#
825182
of 825190
PQR
Re: SemperFITrader post# 825178

Saturday, 05/09/2026 10:51:06 AM

Semper - I am not an expert in that area here for everyone’s information is what Gemini says
Under SEC rules, the disclosure of contingent or future receipts of funds is governed primarily by Item 303 of Regulation S-K (Management’s Discussion and Analysis or MD&A) and the "Probability-Magnitude" test established by the Supreme Court.
There is no "fixed" dollar amount that triggers disclosure; rather, the SEC uses a principles-based approach to determine if the receipt is "material."
1. The MD&A Two-Step Test
For "known uncertainties" or contingent future events, the SEC’s 1989 Interpretive Release provides a specific two-step analysis to determine if disclosure is required under Item 303:
• Step 1: Is it likely to occur? Management must determine if the known event or uncertainty (e.g., a pending legal settlement or a certain future payout) is reasonably likely to come to fruition. If management determines it is not reasonably likely, no disclosure is required.
• Step 2: If it does occur, will it be material? If management cannot determine the likelihood, they must assume the event will occur and evaluate the consequences. Disclosure is required unless management can determine that a material effect on the company’s financial condition or results of operations is not reasonably likely to occur.
2. The Probability-Magnitude Test
In the context of general antifraud provisions (Rule 10b-5), the standard comes from Basic Inc. v. Levinson. For contingent events, materiality depends on a balancing of two factors:
1. Probability: The likelihood that the event will occur.
2. Magnitude: The anticipated intensity of the event in light of the totality of the company's activity.

Would be WUNDERBAR when
MAESTRO unveils ALL her cards vs the piles of unproductive myopic posts witnessed since 2014 on any social media "investment? " forum site

$NWBO re #SPOOFING
All the NW guys we have talked to always said that the weaker of the 7 MMs will likely settle earlierhttps://t.co/HfARpgCtXlhttps://t.co/c9ryIIN6PV

It does appear MAESTRO is in The Cat Birds Seat on ALL FRONTS

Irrespective of the topic or sub topics

— maverick_1 (@maveric92283613) October 10, 2025

#DISRUPTOR #CANCER $NWBO #SPOOFING to RICO 
Collabs: $MRK $AZN $AMGN $REGN $TAK $BMY $JNJ $GILD $RHHBY
DYNAMO BB post
BP IN combo trials NEEDS DC based platform 2 make CI treatments better AND we lease developed scaled platform technology https://t.co/hBysR6dAVB
For GEN WEALTH

— maverick_1 (@maveric92283613) September 4, 2024

DIFFERENT STROKES for DIFFERENT FOLKS